ALX Oncology Holdings Shares Outstanding 2019-2021 | ALXO

ALX Oncology Holdings shares outstanding from 2019 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
ALX Oncology Holdings Annual Shares Outstanding
(Millions of Shares)
2020 18
2019 3
2018 3
ALX Oncology Holdings Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 40
2021-03-31 40
2020-12-31 18
2020-09-30 30
2020-06-30 3
2020-03-31 3
2019-09-30 3
2019-06-30 3
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $3.025B $0.001B
ALX Oncology Holdings a clinical-stage immuno-oncology company. It focuses on developing therapies for patients fighting cancer. The company's product candidate consist ALX148, which is in clinical stage. ALX Oncology Holdings based in Burlingame, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29